Table 3.

Clinical trials of adipose derived stem cells applications.

Disease	Clinical trials	Routine treatment	Effect of ASCs therapy	Autologous or Heterologous	Ref.
Knee osteoarthritis	Phase I	Intra-articular injection	Decrease pain and improve WOMUA index	Autologous	[182]
Degenerative disc disease	Yes	Injection	Decrease low back pain	Autologous	NCT02097862
Hip osteoarthritis	Yes	Percutaneous injections	Regenerate cartilage-like tissue	ASCs	[183]
Heart failure	Phase II	Intramyocardial injection		Heterologous	NCT0267316
Ischemic heart disease	Phase I/II	Intramyocardial injection	Increase myocardial perfusion	Autologous	[184]
Ischemic cardiomyopathy	Phase I	Intravenous injection	Angiogenic effect	Autologous	NCT00426868
Critical limb ischemia	Phase I/II	Intramuscular injection	Angiogenic effect	Autologous	NCT01211028
Chronic myocardial ischemia	Phase I/II	Intramyocardial injection	Angiogenic effect	Heterologous	NCT01556022
Ischemic stroke	Phase II	Intravenous injection	Angiogenic effect	Heterologous	NCT01678534
Stroke	Phase II/III	Intravenous infusion	Angiogenic effect	Heterologous	NCT02849613
Amyotrophic lateral sclerosis	Phase I	Intravenous injection	Safety Improvement of ALS function, FVC	ASCs	NCT02492516
Multiple system atrophy	Phase I	Intrathecal injections	Safety	Autologous	NCT02315027a
	Phase I/II	intrathecally via lumbar puncture	Safety at high dose	Autologous	[185,186]
Spinal cord injury	Phase I/II	Intrathecal transplantation	Recover ASIA and sensory score	Autologous	[187]
Traumatic brain injury	Phase I/II	Injection	Safety Benefits	Autologous	NCT02959294a

WOMUA index, Western Ontario and McMaster Universities Arthritis Index; ALS, amyotrophic lateral sclerosis; FVC, Forced Vital Capacity; ASIA, American Spinal Injury Association.

^aClinical trials are processing.